| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5591401 | Blood Cells, Molecules, and Diseases | 2017 | 5 Pages |
Abstract
A combination of FVIIIÂ +Â FEIBA may be effective and safe as an alternative treatment option for some high-responding inhibitor patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Biology
Authors
Tami Livnat, Ivan Budnik, Sarina Levy-Mendelovich, Einat Avishai, Mudi Misgav, Assaf Arie Barg, Aharon Lubetsky, Tami Brutman-Barazani, Gili Kenet,